Qnexa Reduces Hemoglobin A1c By 1.6% In 56 Weeks

VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced positive results from the DM-230 study, a 56-week, randomized, double-blind, placebo-controlled, efficacy and safety study of Qnexa?, an investigational drug, for the glycemic management of obese type 2 diabetics.

More: continued here

Filed under: Blood on December 19th, 2008